866-997-4948(US-Canada Toll Free)

United States Neuroendocrine Carcinoma Market Report 2018

Published By :

QYResearch

Published Date : Jun 2018

Category :

Pharmaceutical

No. of Pages : 108 Pages

In this report, the United States Neuroendocrine Carcinoma market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Neuroendocrine Carcinoma in these regions, from 2013 to 2025 (forecast).

United States Neuroendocrine Carcinoma market competition by top manufacturers/players, with Neuroendocrine Carcinoma sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Pfizer
Novartis
Chiasma
Ipsen
Abbvie
Valeant
Jubilant
Teva
F.Hoffmann-La Roche
Advanced Accelerator
Mateon
Lexicon

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Chemotherapy
Somatostatin Analogs
Targeted Therapy
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres

Table of Contents

United States Neuroendocrine Carcinoma Market Report 2018
1 Neuroendocrine Carcinoma Overview
1.1 Product Overview and Scope of Neuroendocrine Carcinoma
1.2 Classification of Neuroendocrine Carcinoma by Product Category
1.2.1 United States Neuroendocrine Carcinoma Market Size (Sales Volume) Comparison by Type (2013-2025)
1.2.2 United States Neuroendocrine Carcinoma Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
1.2.3 Chemotherapy
1.2.4 Somatostatin Analogs
1.2.5 Targeted Therapy
1.3 United States Neuroendocrine Carcinoma Market by Application/End Users
1.3.1 United States Neuroendocrine Carcinoma Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 United States Neuroendocrine Carcinoma Market by Region
1.4.1 United States Neuroendocrine Carcinoma Market Size (Value) Comparison by Region (2013-2025)
1.4.2 The West Neuroendocrine Carcinoma Status and Prospect (2013-2025)
1.4.3 Southwest Neuroendocrine Carcinoma Status and Prospect (2013-2025)
1.4.4 The Middle Atlantic Neuroendocrine Carcinoma Status and Prospect (2013-2025)
1.4.5 New England Neuroendocrine Carcinoma Status and Prospect (2013-2025)
1.4.6 The South Neuroendocrine Carcinoma Status and Prospect (2013-2025)
1.4.7 The Midwest Neuroendocrine Carcinoma Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Neuroendocrine Carcinoma (2013-2025)
1.5.1 United States Neuroendocrine Carcinoma Sales and Growth Rate (2013-2025)
1.5.2 United States Neuroendocrine Carcinoma Revenue and Growth Rate (2013-2025)

2 United States Neuroendocrine Carcinoma Market Competition by Players/Suppliers
2.1 United States Neuroendocrine Carcinoma Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Neuroendocrine Carcinoma Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Neuroendocrine Carcinoma Average Price by Players/Suppliers (2013-2018)
2.4 United States Neuroendocrine Carcinoma Market Competitive Situation and Trends
2.4.1 United States Neuroendocrine Carcinoma Market Concentration Rate
2.4.2 United States Neuroendocrine Carcinoma Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Neuroendocrine Carcinoma Manufacturing Base Distribution, Sales Area, Product Type

3 United States Neuroendocrine Carcinoma Sales (Volume) and Revenue (Value) by Region (2013-2018)
3.1 United States Neuroendocrine Carcinoma Sales and Market Share by Region (2013-2018)
3.2 United States Neuroendocrine Carcinoma Revenue and Market Share by Region (2013-2018)
3.3 United States Neuroendocrine Carcinoma Price by Region (2013-2018)

4 United States Neuroendocrine Carcinoma Sales (Volume) and Revenue (Value) by Type (Product Category) (2013-2018)
4.1 United States Neuroendocrine Carcinoma Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Neuroendocrine Carcinoma Revenue and Market Share by Type (2013-2018)
4.3 United States Neuroendocrine Carcinoma Price by Type (2013-2018)
4.4 United States Neuroendocrine Carcinoma Sales Growth Rate by Type (2013-2018)

5 United States Neuroendocrine Carcinoma Sales (Volume) by Application (2013-2018)
5.1 United States Neuroendocrine Carcinoma Sales and Market Share by Application (2013-2018)
5.2 United States Neuroendocrine Carcinoma Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 United States Neuroendocrine Carcinoma Players/Suppliers Profiles and Sales Data
6.1 Pfizer
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Pfizer Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Main Business/Business Overview
6.2 Novartis
6.2.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Novartis Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Main Business/Business Overview
6.3 Chiasma
6.3.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Chiasma Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Main Business/Business Overview
6.4 Ipsen
6.4.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Ipsen Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Main Business/Business Overview
6.5 Abbvie
6.5.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Abbvie Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Main Business/Business Overview
6.6 Valeant
6.6.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Valeant Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Main Business/Business Overview
6.7 Jubilant
6.7.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Jubilant Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Main Business/Business Overview
6.8 Teva
6.8.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Teva Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.8.4 Main Business/Business Overview
6.9 F.Hoffmann-La Roche
6.9.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.9.4 Main Business/Business Overview
6.10 Advanced Accelerator
6.10.2 Neuroendocrine Carcinoma Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Advanced Accelerator Neuroendocrine Carcinoma Sales, Revenue, Price and Gross Margin (2013-2018)
6.10.4 Main Business/Business Overview
6.11 Mateon
6.12 Lexicon

7 Neuroendocrine Carcinoma Manufacturing Cost Analysis
7.1 Neuroendocrine Carcinoma Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Neuroendocrine Carcinoma

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Neuroendocrine Carcinoma Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Neuroendocrine Carcinoma Major Manufacturers in 2017
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Neuroendocrine Carcinoma Market Size (Value and Volume) Forecast (2018-2025)
11.1 United States Neuroendocrine Carcinoma Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Neuroendocrine Carcinoma Sales Volume Forecast by Type (2018-2025)
11.3 United States Neuroendocrine Carcinoma Sales Volume Forecast by Application (2018-2025)
11.4 United States Neuroendocrine Carcinoma Sales Volume Forecast by Region (2018-2025)

12 Research Findings and Conclusion

13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer

List of Table

List of Tables and Figures

Figure Product Picture of Neuroendocrine Carcinoma
Figure United States Neuroendocrine Carcinoma Market Size (K Pcs) by Type (2013-2025)
Figure United States Neuroendocrine Carcinoma Sales Volume Market Share by Type (Product Category) in 2017
Figure Chemotherapy Product Picture
Figure Somatostatin Analogs Product Picture
Figure Targeted Therapy Product Picture
Figure United States Neuroendocrine Carcinoma Market Size (K Pcs) by Application (2013-2025)
Figure United States Sales Market Share of Neuroendocrine Carcinoma by Application in 2017
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinics Examples
Table Key Downstream Customer in Clinics
Figure Oncology Centres Examples
Table Key Downstream Customer in Oncology Centres
Figure Ambulatory Surgery Centres Examples
Table Key Downstream Customer in Ambulatory Surgery Centres
Figure United States Neuroendocrine Carcinoma Market Size (Million USD) by Region (2013-2025)
Figure The West Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Neuroendocrine Carcinoma Sales (K Pcs) and Growth Rate (2013-2025)
Figure United States Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Neuroendocrine Carcinoma Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table United States Neuroendocrine Carcinoma Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table United States Neuroendocrine Carcinoma Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Neuroendocrine Carcinoma Sales Share by Players/Suppliers
Figure 2017 United States Neuroendocrine Carcinoma Sales Share by Players/Suppliers
Figure United States Neuroendocrine Carcinoma Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Neuroendocrine Carcinoma Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Neuroendocrine Carcinoma Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Neuroendocrine Carcinoma Revenue Share by Players/Suppliers
Figure 2017 United States Neuroendocrine Carcinoma Revenue Share by Players/Suppliers
Table United States Market Neuroendocrine Carcinoma Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)
Figure United States Market Neuroendocrine Carcinoma Average Price (USD/Pcs) of Key Players/Suppliers in 2017
Figure United States Neuroendocrine Carcinoma Market Share of Top 3 Players/Suppliers
Figure United States Neuroendocrine Carcinoma Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Neuroendocrine Carcinoma Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Neuroendocrine Carcinoma Product Category
Table United States Neuroendocrine Carcinoma Sales (K Pcs) by Region (2013-2018)
Table United States Neuroendocrine Carcinoma Sales Share by Region (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Share by Region (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Market Share by Region in 2017
Table United States Neuroendocrine Carcinoma Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Neuroendocrine Carcinoma Revenue Share by Region (2013-2018)
Figure United States Neuroendocrine Carcinoma Revenue Market Share by Region (2013-2018)
Figure United States Neuroendocrine Carcinoma Revenue Market Share by Region in 2017
Table United States Neuroendocrine Carcinoma Price (USD/Pcs) by Region (2013-2018)
Table United States Neuroendocrine Carcinoma Sales (K Pcs) by Type (2013-2018)
Table United States Neuroendocrine Carcinoma Sales Share by Type (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Share by Type (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Market Share by Type in 2017
Table United States Neuroendocrine Carcinoma Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Neuroendocrine Carcinoma Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Neuroendocrine Carcinoma by Type (2013-2018)
Figure Revenue Market Share of Neuroendocrine Carcinoma by Type in 2017
Table United States Neuroendocrine Carcinoma Price (USD/Pcs) by Types (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Growth Rate by Type (2013-2018)
Table United States Neuroendocrine Carcinoma Sales (K Pcs) by Application (2013-2018)
Table United States Neuroendocrine Carcinoma Sales Market Share by Application (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Market Share by Application (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Market Share by Application in 2017
Table United States Neuroendocrine Carcinoma Sales Growth Rate by Application (2013-2018)
Figure United States Neuroendocrine Carcinoma Sales Growth Rate by Application (2013-2018)
Table Pfizer Basic Information List
Table Pfizer Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Pfizer Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Pfizer Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Pfizer Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Novartis Basic Information List
Table Novartis Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Novartis Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Novartis Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Novartis Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Chiasma Basic Information List
Table Chiasma Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Chiasma Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Chiasma Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Chiasma Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Ipsen Basic Information List
Table Ipsen Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Ipsen Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Ipsen Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Ipsen Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Abbvie Basic Information List
Table Abbvie Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Abbvie Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Abbvie Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Abbvie Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Valeant Basic Information List
Table Valeant Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Valeant Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Valeant Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Valeant Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Jubilant Basic Information List
Table Jubilant Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Jubilant Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Jubilant Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Jubilant Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Teva Basic Information List
Table Teva Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Teva Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Teva Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Teva Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table F.Hoffmann-La Roche Basic Information List
Table F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Advanced Accelerator Basic Information List
Table Advanced Accelerator Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Advanced Accelerator Neuroendocrine Carcinoma Sales Growth Rate (2013-2018)
Figure Advanced Accelerator Neuroendocrine Carcinoma Sales Market Share in United States (2013-2018)
Figure Advanced Accelerator Neuroendocrine Carcinoma Revenue Market Share in United States (2013-2018)
Table Mateon Basic Information List
Table Lexicon Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Neuroendocrine Carcinoma
Figure Manufacturing Process Analysis of Neuroendocrine Carcinoma
Figure Neuroendocrine Carcinoma Industrial Chain Analysis
Table Raw Materials Sources of Neuroendocrine Carcinoma Major Players/Suppliers in 2017
Table Major Buyers of Neuroendocrine Carcinoma
Table Distributors/Traders List
Figure United States Neuroendocrine Carcinoma Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Neuroendocrine Carcinoma Price (USD/Pcs) Trend Forecast (2018-2025)
Table United States Neuroendocrine Carcinoma Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Neuroendocrine Carcinoma Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Neuroendocrine Carcinoma Sales Volume (K Pcs) Forecast by Type in 2025
Table United States Neuroendocrine Carcinoma Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Neuroendocrine Carcinoma Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Neuroendocrine Carcinoma Sales Volume (K Pcs) Forecast by Application in 2025
Table United States Neuroendocrine Carcinoma Sales Volume (K Pcs) Forecast by Region (2018-2025)
Table United States Neuroendocrine Carcinoma Sales Volume Share Forecast by Region (2018-2025)
Figure United States Neuroendocrine Carcinoma Sales Volume Share Forecast by Region (2018-2025)
Figure United States Neuroendocrine Carcinoma Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *